Calamos Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Calamos Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$550K	Sell	1,108 -726	-40%	-$322K	0.02%	296
2026 Q1	$819K	Buy	1,834 +1,186	+183%	+$553K	0.03%	233
2025 Q4	$294K	Buy	+648	New	+$279K	0.01%	368
2021 Q3	–	Sell	-1,976	Closed	-$398K	–	322
2021 Q2	$398K	Sell	1,976 -22,226	-92%	-$4.65M	0.03%	252
2021 Q1	$5.2M	Buy	24,202 +439	+2%	+$96.4K	0.43%	67
2020 Q4	$5.62M	Buy	23,763 +1,137	+5%	+$261K	0.51%	59
2020 Q3	$6.16M	Sell	22,626 -565	-2%	-$156K	0.7%	38
2020 Q2	$6.73M	Buy	23,191 +644	+3%	+$175K	0.84%	24
2020 Q1	$5.37M	Buy	+22,547	New	+$5.17M	0.82%	31

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Calamos Wealth Management's VRTX Position: Q2 2026 in Review

Calamos Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 40% in Q2 2026, selling an estimated $322K and leaving 1,108 shares worth $550K. The position accounts for 0.02% of the portfolio, ranked #296.

Calamos Wealth Management first reported a position in VRTX in Q1 2020 and has held it in 9 quarters since. The position peaked at $6.73M in Q2 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Calamos Wealth Management held 1,108 shares of Vertex Pharmaceuticals worth $550K as of Q2 2026.
Calamos Wealth Management sold 726 Vertex Pharmaceuticals shares in Q2 2026, an estimated $322K.
Vertex Pharmaceuticals made up 0.02% of Calamos Wealth Management's portfolio in Q2 2026, its #296 holding.
Calamos Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
Calamos Wealth Management's Vertex Pharmaceuticals position peaked at $6.73M in Q2 2020.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.